---
layout: default
title: Sodium Carbonate
parent: Low Evidence (L5)
nav_order: 909
evidence_level: L5
indication_count: 10
---

# Sodium Carbonate
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sodium Carbonate: From an Unspecified Original Indication to Cauda Equina Syndrome

## One-Sentence Summary

Sodium carbonate is an alkalinizing agent, and no original approved indication is recorded for it in the Singapore registration data.
The TxGNN model predicts it may be effective for **cauda equina syndrome**, but this is a graph prediction only.
There are **0 clinical trials** and **0 publications** supporting this direction.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not stated (the registration record has no approved indication text) |
| Predicted New Indication | Cauda equina syndrome |
| TxGNN Prediction Score | 99.80% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for sodium carbonate. It is generally known as an alkalinizing agent. Its original indication cannot be established from the available record, so there is no known therapeutic area to compare against cauda equina syndrome.

No plausible mechanistic link to cauda equina syndrome has been identified. Cauda equina syndrome is a neurological and surgical emergency caused by compression of the lumbosacral nerve roots. Nothing in the data suggests sodium carbonate acts on this condition. The high score (99.80%) reflects a pattern in the knowledge graph, not biological or clinical support. It should be treated as a hypothesis-generating signal only.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Singapore Market Information

| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---------|------|------|-----------|
| SIN11470P | CEFAZIME FOR INJECTION 1 g/vial (CJ Corp) | Injection | Not stated in the record |

The only registered product is an injectable preparation. Its name suggests an antibiotic, so sodium carbonate may be present only as a formulation component. This has not been verified against the product label.

## Safety Considerations

Please refer to the package insert for safety information.

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The prediction rests on the model score alone, with no trials, no literature and no mechanistic link. The sole Singapore registration may involve sodium carbonate only as an excipient, and no safety data are available.

**To proceed, the following is needed:**
- Package insert warnings and contraindications from the HSA website, which currently block safety screening
- Confirmation of whether sodium carbonate is an active ingredient or an excipient in the registered product
- Mechanism of action data from DrugBank
- A credible biological rationale linking sodium carbonate to cauda equina syndrome
- A route-compatibility assessment, since this is currently pending

**Other predictions to consider:**
- Sjögren syndrome has one indirect publication (PMID 27813150, a sodium carbonate oral spray used with oral hygiene), and the model flags it as a research question.
- A full-text review is needed to confirm that study's design before the evidence level can be upgraded.
- Two predicted terms, "obsolete neurogenic bladder (disease)" and "obsolete bundle branch block", are obsolete and should be remapped to current ontology terms before any review.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

